Biomarker Prognostication Across Universal Definition of Heart Failure Stages
Open Access
- 8 August 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 9 (6) , 3876-3887
Abstract
Aim: The Universal Definition of Heart Failure (UDHF) provides a framework for staging risk for HF events. It is not clear whether prognostic biomarkers have different meaning across UDHF stages. We sought to evaluate performance of biomarkers to predict HF events among high-risk patients undergoing coronary and/or peripheral angiography categorized into UDHF stages. Methods: One thousand two hundred thirty-five individuals underwent coronary and/or peripheral angiography were enrolled. Study participants were categorized into UDHF Stage A (at risk), Stage B (pre-HF), and Stage C or D (HF, including end stage) and grouped into Stage A/B and C/D. Biomarkers and clinical variables were used to develop prognostic models. Other measures examined included total HF hospitalizations. Results: Over a median of 3.67 years of follow-up, 155 cardiovascular (CV) deaths occurred, and 299 patients were hospitalized with acute HF. In patients with Stage A/B, galectin-3 (HR = 1.52, P = 0.03), endothelin-1 (HR = 2.16, P = 0.001), and N-terminal pro-B-type natriuretic peptide (NT-proBNP; HR = 1.43, P < 0.001) were associated with incident CV death/HF hospitalization. In Stage C/D, NT-proBNP (HR = 1.26, P = 0.006), soluble urokinase-type plasminogen activator receptor (suPAR; HR = 1.57, P = 0.007) and high-sensitivity C-reactive protein (hs-CRP; HR = 1.15, P = 0.01) were associated with these outcomes. Higher biomarker concentrations were associated with greater total burden of HF events in Stages A/B and C/D. Conclusions: Among higher risk individuals undergoing angiographic procedures, different biomarkers improve risk stratification in different UDHF stages of HF. More precise prognostication may offer a window of opportunity to initiate targeted preventive measures.Keywords
Funding Information
- Hutter Family Professorship
- National Heart, Lung, and Blood Institute (5T32HL094301-12)
- Barry Fellowship
- Hunter Family Foundation
- National Heart, Lung, and Blood Institute (5T32HL094301‐12)
This publication has 36 references indexed in Scilit:
- Charting a Roadmap for Heart Failure Biomarker StudiesJACC: Heart Failure, 2014
- A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functionsJournal of Clinical Epidemiology, 2013
- N-terminal Pro-B-Type Natriuretic Peptide, Left Ventricular Mass, and Incident Heart FailureCirculation: Heart Failure, 2012
- Time from emerging heart failure symptoms to cardiac resynchronisation therapy: impact on clinical responseHeart, 2012
- A Validated Risk Score for In-Hospital Mortality in Patients With Heart Failure From the American Heart Association Get With the Guidelines ProgramCirculation: Cardiovascular Quality and Outcomes, 2010
- suPAR: The Molecular Crystal BallDisease Markers, 2009
- Metabolic Mechanisms in Heart FailureCirculation, 2007
- Mechanisms and Models in Heart FailureCirculation, 2005
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Expression of Endothelin-1 in the Lungs of Patients with Pulmonary HypertensionNew England Journal of Medicine, 1993